Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 7:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 59 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: MMF Placebo Clear all
Completed Phase 3 Interventional Results available

A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.

NCT00377637
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Mycophenolate mofetil (MMF), Cyclophosphamide, Azathioprine, Placebo to Azathioprine, Placebo to Mycophenolate mofetil, Corticosteroid
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years to 75 Years
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
28
States / cities
Huntsville, Alabama • La Jolla, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2011 · Synced Oct 20, 2026, 7:29 PM EDT
Completed Phase 2 Interventional Results available

A Randomized Controlled Clinical Trial of Thymoglobulin® After Liver Transplantation

NCT02544113
View directory record Official record
Conditions
Liver Failure
Interventions
Thymoglobulin, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
4
States / cities
Weston, Florida • Cincinnati, Ohio • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Oct 20, 2026, 7:29 PM EDT
Terminated Phase 4 Interventional

Trial of Calcineurin Inhibitor-Sparing Immunosuppression Regimen in Pediatric Liver Transplantation

NCT00656266
View directory record Official record
Conditions
End-stage Liver Disease, Renal Insufficiency, Renal Failure
Interventions
mycophenolate mofetil, placebo medication
Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 16 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2020 · Synced Oct 20, 2026, 7:29 PM EDT
Terminated Phase 2 Interventional Results available

Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation

NCT01278745
View directory record Official record
Conditions
Cardiac Allograft Vasculopathy, Heart Transplant Recipients
Interventions
Rituximab induction/conventional immunosuppression (tacrolimus, MMF, and steroid taper), Rituximab placebo/conventional immunosuppression (tacrolimus, MMF, and steroid taper)
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
24
States / cities
Beverly Hills, California • Los Angeles, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 20, 2026, 7:29 PM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Effects of an Immunosuppressant Mycophenolate Mofetil or MMF on the Urinary Sodium Excretion Response to Mental Stress

NCT02432339
View directory record Official record
Conditions
Psychological Stress, Hypertension, Renal
Interventions
mycophenolate mofetil (MMF), Placebo
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 20, 2019 · Synced Oct 20, 2026, 7:29 PM EDT
Completed Phase 3 Interventional

A Continuation Study to Assess the Effect of CellCept in Patients With Myasthenia Gravis.

NCT00408213
View directory record Official record
Conditions
Myasthenia Gravis Generalised
Interventions
mycophenolate mofetil [CellCept], Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 80 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
3
States / cities
Sun City, Arizona • Sacramento, California • Upland, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 23, 2008 · Synced Oct 20, 2026, 7:29 PM EDT
Completed Phase 2 Interventional Results available

Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis

NCT02370693
View directory record Official record
Conditions
Lung Diseases, Interstitial, Systemic Sclerosis, Scleroderma
Interventions
Bortezomib, Placebo, Mycophenolate mofetil
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Oct 20, 2026, 7:29 PM EDT
Completed Phase 2 Interventional Results available

A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease

NCT04734197
View directory record Official record
Conditions
Dry Eye Disease
Interventions
SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate), Mycophenolic Acid 0.1%, Mycophenolic Acid 0.3%, Betamethasone Sodium Phosphate 0.01%, Placebo Comparator: Vehicle, Cyclosporine 0.05% Ophthalmic Emulsion, Lifitegrast 5% Ophthalmic Solution
Drug
Lead sponsor
Surface Ophthalmics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
40
States / cities
Phoenix, Arizona • Azusa, California • Hemet, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 11, 2025 · Synced Oct 20, 2026, 7:29 PM EDT
Terminated Phase 3 Interventional Results available

Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD)

NCT00089141
View directory record Official record
Conditions
Cancer
Interventions
mycophenolate mofetil, placebo
Drug
Lead sponsor
Martin, Paul
Other
Eligibility
4 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
15
States / cities
Duarte, California • Stanford, California • Gainesville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated May 3, 2013 · Synced Oct 20, 2026, 7:29 PM EDT
Active, not recruiting Phase 2 Interventional

Mesenchymal Stromal Cells in Living Donor Kidney Transplantation

NCT03478215
View directory record Official record
Conditions
Renal Transplantation, Mesenchymal Stem Cells
Interventions
Mesenchymal Stromal Stem Cells (MSCs) Infusion, Normal Saline (Placebo) Infusion
Biological · Other
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 20, 2026, 7:29 PM EDT
Terminated Phase 2 Interventional Results available

An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis

NCT03943147
View directory record Official record
Conditions
Lupus Nephritis
Interventions
BMS-986165, Placebo, Mycophenolate Mofetil
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
40
States / cities
Birmingham, Alabama • Fresno, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Oct 20, 2026, 7:29 PM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients

NCT03663335
View directory record Official record
Conditions
Kidney Transplantation
Interventions
CFZ533 - Cohort 1/Cohort 2, Mycophenolate Mofetil (MMF), Corticosteroids (CS), Tacrolimus, Induction therapy: basiliximab, Induction therapy: rabbit anti-thymocyte globulin (rATG), Maintenance population: EC-MPS, Maintenance population: MMF, Placebo 1 mL
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 20, 2026, 7:29 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis

NCT04221477
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Obinutuzumab, MMF, Prednisone, Placebo, Methylprednisolone, Acetaminophen, Diphenhydramine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
18
States / cities
Birmingham, Alabama • Beverly Hills, California • Fontana, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 20, 2026, 7:29 PM EDT
Terminated Phase 2 Interventional Results available

Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus

NCT05306873
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Mycophenolate Mofetil, Placebo for Mycophenolate Mofetil, Voclosporin, Placebo for Voclosporin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
10
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 20, 2026, 7:29 PM EDT
Completed Phase 2 Interventional Results available

Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney

NCT00035555
View directory record Official record
Conditions
Graft Rejection, Kidney Transplantation, Renal Transplantation
Interventions
Belatacept, Cyclosporine, Mycophenolate mofetil (MMF), Corticosteroids
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
12
States / cities
San Francisco, California • Atlanta, Georgia • Baltimore, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Oct 20, 2026, 7:29 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)

NCT00683930
View directory record Official record
Conditions
Pemphigus Vulgaris (PV)
Interventions
Mycophenolate Mofetil 2 g/Day, Mycophenolate Mofetil (MMF) 3 g/Day, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 70 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
5
States / cities
Los Angeles, California • Atlanta, Georgia • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Oct 20, 2026, 7:29 PM EDT
Completed Phase 4 Interventional Results available

Enteric-coated Mycophenolate Sodium (EC-MPS) and Mycophenolate Mofetil (MMF) in Renal Transplant Patients With Gastrointestinal (GI) Intolerance

NCT00400400
View directory record Official record
Conditions
Renal Transplantation
Interventions
Enteric-coated mycophenolate sodium (EC-MPS), Mycophenolate mofetil, Placebo to mycophenolate sodium, Placebo to mycophenolate mofetil
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
53
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2011 · Synced Oct 20, 2026, 7:29 PM EDT
Completed Phase 2 Interventional Results available

B Cell Induction in Pediatric Lung Transplantation

NCT02266888
View directory record Official record
Conditions
Lung Transplant
Interventions
Rituximab (Rituxan®), Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 21 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
7
States / cities
Palo Alto, California • Boston, Massachusetts • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Oct 20, 2026, 7:29 PM EDT
Withdrawn Phase 2 Interventional

Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial

NCT07349771
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Axatilimab, Biospecimen Collection, Bone Marrow Aspiration, Computed Tomography, Cyclophosphamide, Magnetic Resonance Imaging, Mycophenolate Mofetil, Placebo Administration, Positron Emission Tomography, Skin Biopsy, Tacrolimus, X-Ray Imaging
Procedure · Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 20, 2026, 7:29 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)

NCT06503731
View directory record Official record
Conditions
Antibody-mediated Rejection
Interventions
Efgartigimod PH20 SC - prefilled syringe, Placebo PH20 SC - prefilled syringe
Combination Product · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 20, 2026, 7:29 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)

NCT02550652
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Mycophenolate Mofetil/Mycophenolic Acid, Obinutuzumab, Placebo, Methylprednisolone, Prednisone
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
7
States / cities
La Jolla, California • Palo Alto, California • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Oct 20, 2026, 7:29 PM EDT
Completed Phase 2 Interventional Results available

Effects of Inhibiting Early Inflammation in Kidney Transplant Patients

NCT02495077
View directory record Official record
Conditions
Kidney Transplant
Interventions
Infliximab, Methylprednisolone, Mycophenolate Mofetil, Tacrolimus, Thymoglobulin®, Acetaminophen, Loratadine, Placebo for Infliximab, Prednisone, Diphenhydramine
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 20, 2026, 7:29 PM EDT
Completed Phase 2 Interventional Results available

Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate

NCT03221257
View directory record Official record
Conditions
Scleroderma, Systemic, Interstitial Lung Disease
Interventions
Pirfenidone (PFD), Placebo (Plac), Mycophenolate Mofetil (MMF)
Drug
Lead sponsor
Michael Roth
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
16
States / cities
Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Oct 20, 2026, 7:29 PM EDT
Completed Phase 3 Interventional Results available

Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)

NCT01002742
View directory record Official record
Conditions
Graft-versus-Host Disease, Immune System Disorders
Interventions
Mycophenolate Mofetil, Placebo
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Not listed
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
36
States / cities
Duarte, California • La Jolla, California • Stanford, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 20, 2026, 7:29 PM EDT